Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Evaluation of the Immune Response to a Modified Dosing Schedule for the Quadrivalent Human Papillomavirus (HPV) Vaccine, Potential Extramural Projects (PEP) 2008-R-22, 21137 [E8-8370]

Download as PDF Federal Register / Vol. 73, No. 76 / Friday, April 18, 2008 / Notices (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting. Time and Date: 1 p.m.–2 p.m., May 14, 2008 (Closed). Place: Teleconference. Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463. Matters to be Discussed: The meeting will include the review, discussion, and evaluation of ‘‘The Effect of Prenatal Bleeding on Pregnancy Outcomes in Women with a Previously Undiagnosed Bleeding Disorder, PEP 2008–R–27.’’ Contact Person for More Information: Linda Shelton, Program Specialist, Coordinating Center for Health and Information Service, Office of the Director, CDC, 1600 Clifton Road, NE., Mailstop E21, Atlanta, GA 30333, Telephone (404) 498– 1194. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry. Dated: April 10, 2008. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. E8–8363 Filed 4–17–08; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Impact of Cultural and Socioeconomic Factors on Post-Treatment Surveillance among African Americans with Colorectal Cancer, Potential Extramural Project (PEP) 2008–R–03 pwalker on PROD1PC71 with NOTICES In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting. Time and Date: 1 p.m.–3 p.m., May 29, 2008 (Closed). Place: Teleconference. Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463. Matters to be Discussed: The meeting will include the review, discussion, and 17:38 Apr 17, 2008 Jkt 214001 Dated: April 9, 2008. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. E8–8368 Filed 4–17–08; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): A Retrospective Evaluation of Patterns of Care for American Indian and Alaska Native Men With Elevated Prostate Specific Antigen, Potential Extramural Project (PEP) 2008–R–15 In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting: Centers for Disease Control and Prevention VerDate Aug<31>2005 evaluation of ‘‘Impact of Cultural and Socioeconomic Factors on Post-Treatment Surveillance among African Americans with Colorectal Cancer, PEP 2008–R–03.’’ Contact Person for More Information: Linda Shelton, Program Specialist, Coordinating Center for Health and Information Service, Office of the Director, CDC, 1600 Clifton Road, NE., Mailstop E21, Atlanta, GA 30333, Telephone (404) 498– 1194. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry. Time and Date: 1 p.m.–2:30 p.m., May 19, 2008 (Closed). Place: Teleconference. Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463. Matters to be Discussed: The meeting will include the review, discussion, and evaluation of ‘‘A Retrospective Evaluation of Patterns of Care for American Indian and Alaska Native Men with Elevated Prostate Specific Antigen, PEP 2008–R–15.’’ Contact Person for More Information: Linda Shelton, Program Specialist, Coordinating Center for Health and Information Service, Office of the Director, CDC, 1600 Clifton Road, NE., Mailstop E21, Atlanta, GA 30333, Telephone (404) 498– 1194. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and PO 00000 Frm 00043 Fmt 4703 Sfmt 4703 21137 other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry. Dated: April 10, 2008. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. E8–8369 Filed 4–17–08; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Evaluation of the Immune Response to a Modified Dosing Schedule for the Quadrivalent Human Papillomavirus (HPV) Vaccine, Potential Extramural Projects (PEP) 2008–R–22 In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting. Time And Date: 1 p.m.–2 p.m., May 15, 2008 (Closed). Place: Teleconference. Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463. Matters to be Discussed: The meeting will include the review, discussion, and evaluation of ‘‘Evaluation of the Immune Response to a Modified Dosing Schedule for the Quadrivalent HPV Vaccine, PEP 2008–R– 22.’’ Contact Person for More Information: Linda Shelton, Program Specialist, Coordinating Center for Health and Information Service, Office of the Director, CDC, 1600 Clifton Road, NE., Mailstop E21, Atlanta, GA 30333, Telephone (404) 498– 1194. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry. Dated: April 10, 2008. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. E8–8370 Filed 4–17–08; 8:45 am] BILLING CODE 4163–18–P E:\FR\FM\18APN1.SGM 18APN1

Agencies

[Federal Register Volume 73, Number 76 (Friday, April 18, 2008)]
[Notices]
[Page 21137]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-8370]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Disease, Disability, and Injury Prevention and Control Special 
Emphasis Panel (SEP): Evaluation of the Immune Response to a Modified 
Dosing Schedule for the Quadrivalent Human Papillomavirus (HPV) 
Vaccine, Potential Extramural Projects (PEP) 2008-R-22

    In accordance with Section 10(a)(2) of the Federal Advisory 
Committee Act (Pub. L. 92-463), the Centers for Disease Control and 
Prevention (CDC) announces the aforementioned meeting.

    Time And Date: 1 p.m.-2 p.m., May 15, 2008 (Closed).
    Place: Teleconference.
    Status: The meeting will be closed to the public in accordance 
with provisions set forth in Section 552b(c)(4) and (6), Title 5 
U.S.C., and the Determination of the Director, Management Analysis 
and Services Office, CDC, pursuant to Public Law 92-463.
    Matters to be Discussed: The meeting will include the review, 
discussion, and evaluation of ``Evaluation of the Immune Response to 
a Modified Dosing Schedule for the Quadrivalent HPV Vaccine, PEP 
2008-R-22.''
    Contact Person for More Information: Linda Shelton, Program 
Specialist, Coordinating Center for Health and Information Service, 
Office of the Director, CDC, 1600 Clifton Road, NE., Mailstop E21, 
Atlanta, GA 30333, Telephone (404) 498-1194.
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register notices pertaining 
to announcements of meetings and other committee management 
activities, for both CDC and the Agency for Toxic Substances and 
Disease Registry.

    Dated: April 10, 2008.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease 
Control and Prevention.
[FR Doc. E8-8370 Filed 4-17-08; 8:45 am]
BILLING CODE 4163-18-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.